Impact of switching to infliximab biosimilars on treatment patterns among US veterans receiving innovator infliximab-Reference-Cited by-同舟云学术

Impact of switching to infliximab biosimilars on treatment patterns among US veterans receiving innovator infliximab

Published:2022-02-18 Issue:4 Volume:38 Page:613-627
ISSN:0300-7995
Container-title:Current Medical Research and Opinion
language:en
Short-container-title:Current Medical Research and Opinion

Author:

Lin Iris¹^ORCID,Melsheimer Richard²^ORCID,Bhak Rachel H.³,Lefebvre Patrick⁴,DerSarkissian Maral⁵,Emond Bruno⁴^ORCID,Lax Angela³,Nguyen Catherine⁵,Wu Melody³^ORCID,Young-Xu Yinong⁶

Affiliation:

1. Janssen Scientific Affairs, LLC, Horsham, PA, USA

2. Janssen Biologics BV, Leiden, the Netherlands

3. Analysis Group, Inc, Boston, Massachusetts, USA

4. Analysis Group, Inc, Montréal, Québec, Canada

5. Analysis Group, Inc, Los Angeles, California, USA

6. White River Junction VA Medical Center, White River Junction, VT, USA

Publisher

Informa UK Limited

Subject

General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/03007995.2022.2037846

Reference61 articles.

1. A Systematic Review of Factors Associated with Non-Adherence to Treatment for Immune-Mediated Inflammatory Diseases

2. Prevalence of rheumatoid arthritis in the United States adult population in healthcare claims databases, 2004–2014

3. Incidence and Prevalence of Crohn’s Disease and Ulcerative Colitis in Olmsted County, Minnesota From 1970 Through 2010

4. Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution

5. The expanding role of biologic therapy for IBD

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Systematic review: effectiveness and safety of switching between originator infliximab and biosimilar infliximab in patients with inflammatory bowel disease;Expert Opinion on Biological Therapy;2024-07-02

2. Outcomes after anti-tumour necrosis factor originator to biosimilar switching in children and young people with juvenile idiopathic arthritis in the UK: a national cohort study;The Lancet Rheumatology;2024-07

3. Outcomes following switching from etanercept originator to etanercept biosimilar in 1024 patients with RA: a matched-analysis of the BSRBR-RA;Rheumatology;2023-09-06

4. Author’s Response to Letter to the Editor - Re: Lin I, Melsheimer R, Bhak RH, et al. Impact of switching to infliximab biosimilars on treatment patterns among US veterans receiving innovator infliximab. Curr Med Res Opin. 2022;38(4):613–627;Current Medical Research and Opinion;2022-11-07